← Frontiers in Hematology

Papers in Frontiers in Hematology

Page 3 · newest first

101. Targeting the bone marrow niche, moving towards leukemia eradicationFrontiers in Hematology · 2024
102. Real-world analysis of the underdiagnosis, clinical outcomes and associated burden of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in the United StatesFrontiers in Hematology · 2024
103. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targetsFrontiers in Hematology · 2024
104. Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescentFrontiers in Hematology · 2024
105. The sweet symphony of N-glycans in myeloid malignanciesFrontiers in Hematology · 2024
106. Congenital dyserythropoietic anemia type II and ineffective erythropoiesis: challenges in diagnosis and managementFrontiers in Hematology · 2024
107. Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma NetworkFrontiers in Hematology · 2024
108. Novel cryopreservation medium for enhanced stability of T cells at −80°CFrontiers in Hematology · 2024
109. First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in GermanyFrontiers in Hematology · 2024
110. Exploring extramedullary hematopoiesis: unraveling the hematopoietic microenvironmentsFrontiers in Hematology · 2024
111. Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysisFrontiers in Hematology · 2024
112. AL amyloidosis: an overview on diagnosis, staging system, and treatmentFrontiers in Hematology · 2024
113. Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple MyelomaFrontiers in Hematology · 2024
114. Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosisFrontiers in Hematology · 2024
115. Evaluating the effectiveness of COVID-19 vaccines in adults with sickle cell disease during the Omicron period of COVID-19 pandemicFrontiers in Hematology · 2024
116. Constructing a novel clinical indicator model to predict the occurrence of thalassemia in pregnancy through machine learning algorithmFrontiers in Hematology · 2024
117. Blood pharming: exploring the progress and hurdles in producing in-vitro red blood cells for therapeutic applicationsFrontiers in Hematology · 2024
118. Phase II single-arm study of a combination of obinutuzumab and venetoclax in early relapsed or refractory diffuse large B-cell lymphoma—final results of the AGMT NHL15B studyFrontiers in Hematology · 2024
119. Asymmetric cell division of hematopoietic stem cells: recent advances, emerging concepts, and future perspectivesFrontiers in Hematology · 2024
120. Case report: Donor lymphocyte infusion and blinatumomab as treatment for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantationFrontiers in Hematology · 2024
121. The impact of NETosis on hematological malignancies as a promising therapeutic targetFrontiers in Hematology · 2024
122. Management of secondary immunodeficiency in hematological malignancies: a Delphi consensus from the Middle EastFrontiers in Hematology · 2024
123. Case report: Childhood erythrocytosis due to hypermanganesemia caused by homozygous SLC30A10 mutationFrontiers in Hematology · 2024
124. Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinibFrontiers in Hematology · 2024
125. Exploring the intricate cross-talk between clonal expansion and the bone marrow nicheFrontiers in Hematology · 2024
126. Hypersialylation and multiple myelomaFrontiers in Hematology · 2024
127. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancerFrontiers in Hematology · 2024
128. Predicting factors of survival rates among alpha- and beta-thalassemia patients: a retrospective 10-year data analysisFrontiers in Hematology · 2024
129. How artificial intelligence revolutionizes the world of multiple myelomaFrontiers in Hematology · 2024
130. De novo drug design through artificial intelligence: an introductionFrontiers in Hematology · 2024
131. Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemiaFrontiers in Hematology · 2024
132. Generation, characterization, and use of EKLF(Klf1)/CRE knock-in mice for cell-restricted analysesFrontiers in Hematology · 2024
133. Persistent hypersplenism following successful hematopoietic stem cell transplantation: unraveling the cellular components of extramedullary residual disease and donor hematopoiesis—a case reportFrontiers in Hematology · 2024
134. Vhl deletion in Dmp1-expressing cells alters MEP metabolism and promotes stress erythropoiesisFrontiers in Hematology · 2024
135. R-loops in normal and malignant hematopoiesisFrontiers in Hematology · 2023
136. Bcl-2 inhibition in the treatment of hematologic malignanciesFrontiers in Hematology · 2023
137. Differential roles of prostaglandin E2 EP4 receptor on stromal cell populations for hematopoietic stem and progenitor cell functionFrontiers in Hematology · 2023
138. Glycosylation as regulator of human B-cell leukaemias in bone marrowFrontiers in Hematology · 2023
139. 4SCAR2.0 therapy for the management of post-transplantation relapse of B-cell acute lymphoblastic leukemiaFrontiers in Hematology · 2023
140. Improvement in survival of acute myeloid leukemia and myelodysplastic syndrome patients following allogeneic transplant: a long-term institutional experienceFrontiers in Hematology · 2023
141. MicroRNA profiling in aplastic anemia reveals similarities between secondary myelodysplastic syndromes arising from clonal progression and de novo MDSFrontiers in Hematology · 2023
142. Depletion of tet2 results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndromeFrontiers in Hematology · 2023
143. Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trialFrontiers in Hematology · 2023
144. Drug exporter expression correlates with group 3 innate lymphoid cell resistance to immunosuppressive agentsFrontiers in Hematology · 2023
145. The link between immune thrombocytopenia and the cytokine profile: a bridge to new therapeutical targetsFrontiers in Hematology · 2023
146. Knowledge, attitude, and practice of physicians regarding pain management in patients with Sickle cell diseaseFrontiers in Hematology · 2023
147. Abatacept and T-cell costimulation blockade—shifting the paradigm in the prevention of graft-versus-host diseaseFrontiers in Hematology · 2023
148. A systematic review investigating advances in gene therapy for Fanconi anemia over the last three decadesFrontiers in Hematology · 2023
149. Economic burden of sickle cell disease in Sweden: a population-based national register study with 13 years follow upFrontiers in Hematology · 2023
150. Waldenström Macroglobulinemia diagnosis, risk assessment and treatment in Portugal – results from a Delphi-like PanelFrontiers in Hematology · 2023